Inicio > SRIVASTAVA, GIRISH KUMAR

SRIVASTAVA, GIRISH KUMAR

INVESTIGADOR DISTINGUIDO SENIOR
Cirugía, Oftalmología, Otorrinolaringología y Fisioterapia
Grupo de Retina
 
girishkumar.srivastava@uva.es

Índice H en Scopus: 13
 

[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74457]], camposKey:1029-8428 2022-12-01 Advanced Therapy and Clinical Trials to Treat Patients with Optic Nerve Diseases17391757, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74458]], camposKey:0914-7470 2022-07-01 Factors influencing mesenchymal stromal cells in in vitro cellular models to study retinal pigment epithelial cell rescue10051015, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66604]], camposKey:0721-832X 2022-01-01 Acute intraocular toxicity caused by perfluorocarbon liquids: safety control systems of medical devices00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65214]], camposKey:2045-2322 2021-01-12 Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65911]], camposKey:1687-966X 2020-06-27 Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65217]], camposKey:0146-0404 2020-06-01 Is the new ISO 16672.2: 2019 the best prevention to avoid future cases of acute intraocular toxicity by perfluorocarbon liquids?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51256]], camposKey:0273-2300 2020-01-01 Chemical compounds causing severe acute toxicity in heavy liquids used for intraocular surgery1045270, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71255]], camposKey:0146-0404 2019-07-01 Mesenchymal stem cells conditioned medium produced on nicotinamide and/or vasoactive intestinal peptide action improve antioxidative/neuroprotective properties in vitro00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43077]], camposKey:0007-1161 2019-01-01 Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: Failure of another indirect cytotoxicity analysis4954, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43073]], camposKey:0146-0404 2019-01-01 Chemical considerations regarding the H-value methodology and its relation with toxicity determination33633364, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53048]], camposKey:0146-0404 2019-01-01 Clinical characteristics of proven acute intraocular toxicity by perfluorocarbon liquids (PFCL) used in retinal surgery00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53049]], camposKey:0146-0404 2019-01-01 Cytotoxicity evaluation of toxic substances identified in recent reported toxic lots of perfluorocarbon liquids used in intraocular surgery in patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49599]], camposKey:0014-4835 2019-01-01 Mesenchymal stem cells provide paracrine neuroprotective resources that delay degeneration of co-cultured organotypic neuroretinal cultures00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71262]], camposKey:0146-0404 2018-07-01 Mesenchymal stem cells reduce neuroretinal degeneration in vitro00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49606]], camposKey:0721-832X 2018-01-01 Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits125134, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11666]], camposKey:2045-2322 2018-01-01 Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49603]], camposKey:0030-3755 2018-01-01 Retinal toxicity of medical devices used during vitreoretinal surgery: A critical overview236243, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52974]], camposKey:0146-0404 2018-01-01 Toxicity of an endotamponade made by a mixture of perfluorooctane and perfluorohexyloctane evaluated by a new cytotoxicity method00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39306]], camposKey:0146-0404 2017-06-01 Acute retinal toxic damage by AlaOcta (R) a liquid perfluorooctane liquid used in retinal detachment surgery. Clinical picture and functional consequences00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71270]], camposKey:0146-0404 2017-06-01 Evaluation of neurotrophic factors secreted by mesenchymal stem cells in co-culture with porcine neuroretinas00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10084]], camposKey:0275-004X 2017-01-01 Acute retinal damage after using a toxic perfluoro-octane for vitreo-retinal surgery11401151, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52640]], camposKey:1755-375X 2017-01-01 Effects of plasma kallikrein inhibitors in an in vitro RPE oxidative stress model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39307]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytotoxicity in human retinal pigment epithelial cell culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39308]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytoxicity in porcine neuroretina organotypic culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71272]], camposKey:1043-0342 2016-11-01 Preclinical safety and feasibility of intraocular injection of human mesenchymal stem cells in immunocompetent pigmented-rabbit00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51252]], camposKey:1090-0535 2016-01-01 A novel coculture model of porcine central neuroretina explants and retinal pigment epithelium cells243253, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52639]], camposKey:1948-0210 2016-01-01 Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials376383, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10049]], camposKey:0030-3755 2016-01-01 Perfluorocarbon Liquids Toxicity: A Sanitary Alert6363, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53483]], camposKey:2605-3535 2016-01-01 Schwann cells culture with adipose stem cells and neuregulin to determine influencing factors applicable in nerve regeneration00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71275]], camposKey:0146-0404 2015-06-01 A NEW METHOD FOR IMPROVING STEM CELLS OBTAINMENT FROM THE PORCINE CILIARY BODY00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71278]], camposKey:0146-0404 2015-06-01 Intravitreal mesenchymal stem cells are safe and well-tolerated in pigmented-rabbit eyes00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71277]], camposKey:0146-0404 2015-06-01 Retinal pigment epithelium cells protect neuroretina from spontaneous degenerative modifications in a porcine co-culture model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53466]], camposKey:1948-0210 2015-01-01 Current focus of stem cell application in retinal repair641648, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53484]], camposKey:2278-4357 2015-01-01 EVALUATION OF IN VITRO ANTIMICROBIAL ACTIVITY AND ESSENTIAL OIL COMPOSITION OF ETHANOL EXTRACT OF VIOLA ODORATA L. LEAVES11211129, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71266]], camposKey:0146-0404 2014-04-01 An organotypic culture model of porcine neuroretina supplemented with porcine retinal pigment epithelium (pRPE) cells to simulate an ex vivo subretinal space00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71268]], camposKey:0146-0404 2014-04-01 Human adipose tissue derived mesenchymal stem cells (hAD-MSCs) together with different combinations of factors delay the degeneration of human neuroretina in indirect co-culture system00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50771]], camposKey:2211-5420 2014-01-01 Basement membrane promotes ciliary body derived cell spheres formation112118, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=7594]], camposKey:1549-3296 2014-01-01 Bioactive substrates for human retinal pigment epithelial cell growth from elastin-like recombinamers639646, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49616]], camposKey:2314-6133 2014-01-01 Chitosan feasibility to retain retinal stem cell phenotype and slow proliferation for retinal transplantation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=6905]], camposKey:0302-766X 2014-01-01 Triple-layered mixed co-culture model of RPE cells with neuroretina for evaluating the neuroprotective effects of adipose-MSCs705716, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=35038]], camposKey:1090-0535 2013-01-01 Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina894903, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=13970]], camposKey:0213-3911 2013-01-01 Adipose derived mesenchymal stem cells partially rescue mitomycin C treated ARPE19 cells from death in co-culture condition15771583, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38600]], camposKey:0022-1759 2013-01-01 Flow cytometry assessment of the purity of human retinal pigment epithelial primary cell cultures6168, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53462]], camposKey:0175-7598 2011-01-01 An exopolysaccharide produced by the novel halophilic bacterium Halomonas stenophila strain B100 selectively induces apoptosis in human T leukaemia cells345355, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=317]], camposKey:1549-3296 2011-01-01 Elastin-like recombinamers as substrates for retinal pigment epithelial cell growth243250, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54740]], camposKey:1755-375X 2011-01-01 Evaluation of human retinal pigment epithelial cells growth on elastin-like recombinamers substrates00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38602]], camposKey:0014-4835 2011-01-01 Trypan Blue staining method for quenching the autofluorescence of RPE cells for improving protein expression analysis956962, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52831]], camposKey:1825-0572 2009-01-01 Cell therapies for dry forms of age-related macular degeneration: Therapeutic alternatives are currently in development for atrophic AMD7375, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53463]], camposKey:0882-0139 2008-01-01 UVB-induced murine bone marrow derived macrophages and apoptosis293313, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53464]], camposKey:0969-7128 2005-01-01 Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences715723][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64237]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62964]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64237]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62964]]][][][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=30474]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145636934]]][][][][][][][][][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e990a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e869f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e863f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8a05, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8413, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8d94, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8729, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e85ec, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e90c9, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8623, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8ddc, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e962d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e93b7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e853a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8537, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8fbd, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e93f7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8e03, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8f08, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e86ba, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8e89, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8388, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e8efb, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5e886e][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=61593]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=61593]]][][com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1460]], com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1278]], com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1005]]][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@465521], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c00], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c25], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41316b], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5be0a2], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413bdc]][][][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1676e, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@155c5][]

PUBLICACIONES

Artículos de revista (50)

Srivastava G.K.; Lopez-Paniagua M.; Crespo Millas S. Advanced Therapy and Clinical Trials to Treat Patients with Optic Nerve Diseases . NEUROTOXICITY RESEARCH 2022; 40(6): 1739-1757.

Enlace a la publicación
Ver Todos
 

AYUDA A LA INVESTIGACIÓN

Proyectos (6)

RED DE ENFERMEDADES INFLAMATORIAS. Equipo Investigadores: COCO MARTIN, ROSA MARIA (IP); PASTOR IDOATE, SALVADOR (IP); BLAZQUEZ ARAUZO, FRANCISCO; SOBAS ABAD, EVA MARIA; FERNANDEZ BUENO, IVAN; SANABRIA RUIZ COLMENARES, MARIA ROSA; SRIVASTAVA, GIRISH KUMAR; USATEGUI MARTIN, RICARDO; MALDONADO LÓPEZ, MIGUEL JOSÉ; COCO MARTIN, ROSA MARIA; PASTOR IDOATE, SALVADOR; LOPEZ MIGUEL, ALBERTO. Personal Contratado: GUANTAY SOLIS, CARLA DANIELA; GALINDO CABELLO, NADIA REGINA. RD21/0002/0017. Entidades Participantes: UNIVERSIDAD DE VALLADOLID (UVa). Entidades Financiadoras: UNIÓN EUROPEA.-NEXT GENERATION UE, PLAN DE RECUPERACIÓN, TRANSFORMACIÓN Y RESILIENCIA, MICINN. MINISTERIO DE CIENCIA E INNOVACIÓN , INSTITUTO DE SALUD CARLOS III. 01/01/2022-31/12/2024

Next Generation-UEMnisterio de Ciencia e InnovaciónInstituto de Salud Carlos IIIPlan de Recuperación, transformación y Resiliencia
Ver Todos

Convenios/Contratos OTC (24)

Evaluación preclínica de la citotoxicidad de Siobal ¿ S5000 ¿ (aceite de silicona).. Equipo Investigadores: FERNANDEZ BUENO, IVAN (IP); PASTOR JIMENO, JOSE CARLOS; SRIVASTAVA, GIRISH KUMAR; ANDRES IGLESIAS, CRISTINA. Entidades Participantes: FUNDACION GENERAL DE LA UNIVERSIDAD DE VALLADOLID.. Entidades Financiadoras: AJL OPHTHALMIC SA .. 01/10/2021

Ver Todos

Otras ayudas y becas (2)

CONTRATO PREDOCTORAL DE MARTÍNEZ RODRÍGUEZ, SOFÍA: PRODUCCIÓN DE COMPOSICIONES FARMACÉUTICAS CON EFECTO NEUROPROTECTOR PARA LA DEGENERACIÓN RETINIANA. SRIVASTAVA, GIRISH KUMAR (Director). MARTÍNEZ RODRÍGUEZ, SOFÍA (Beneficiario). 01/05/2023 - 30/04/2027. 94.700,46 EUR.

Banco SantanderUniversidad de Valladolid
Ver Todos
 

OTROS

Tesis doctorales (2)


 
Ver Todos

Patentes (3)

SINGH, Amar Kumar SRIVASTAVA, Girish Kumar IVAN FERNANDEZ BUENO MANUEL JOSE GAYOSO RODRIGUEZ JOSE CARLOS PASTOR JIMENO. COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES RETINIANAS DEGENERATIVAS. P201331743
Ver Todos

Estancias de investigación (1)

ESTANCIA DE INVESTIGACION: CTER, NATIONAL UNIVERSITY OF MALAYSIA. 14/09/2023 - 13/10/2023
     CTERM, NATIONAL UNIVERSITY OF MALAYSIA. ( MALASIA )


Ver Todos

Proyectos de innovación docente (2)

Formación con prioridad online sobre presencial para promocionar internacionalización universitaria - PID2022/143. Universidad de Valladolid. 01/09/2022.
Ver Todos
Cargando información ...
Universidad de Valladolid - Copyright Universidad de Valladolid - Todos los derechos reservados